InvestorsHub Logo
Followers 68
Posts 506
Boards Moderated 0
Alias Born 08/14/2020

Re: None

Wednesday, 02/10/2021 7:34:04 AM

Wednesday, February 10, 2021 7:34:04 AM

Post# of 44690
I saw that the length of stay was statistically significantly less with Zyesami. This is the metric for which therapeutics have been granted EUAs thus far. I saw that the standard of care has improved which took away the 28 day mortality difference. I saw more analysis is being done, more reporting on that analysis will be forthcoming and they will continue to work with US regulatory agencies. I added yesterday and have not released a single share. I don't have a crystal ball but the brass ones have served me well.

Best,
JB

Disclaimer

All of my posts are just my own opinion and not advice to buy, sell or trade any stock, security or anything else for that matter. I post my own personal thoughts and information that I have found regarding positions that I am invested in.